GSK Gets Marketing Rights For Labtec Topical Patch

The product is based on Labtec’s proprietary LabiPatch platform technology, which is especially suitable for easy, convenient application of patches on the delicate surface of the lip.

Labtec claimed that encompassing patches with and without active ingredients, the LabiPatch technology is designed to promote the healing process by maintaining a moist and optimal healing environment.

Ingo Lehrke, managing director of Labtec, said: “In GlaxoSmithKline we have found an outstanding development and marketing partner for our innovative patch technology. We are confident that this partnership will deliver improved therapy options for a multitude of patients suffering from cold sores.”

Labtec is a drug delivery company with a specific focus on transdermal and topical patches as well as fast-dissolving oral films. A wholly owned subsidiary of tesa SE and part of the Beiersdorf group of companies, Labtec is the pharmaceutical specialist in a truly global family of companies.